Transcription
CDC73 encodes a 2.7 kb mRNA with a 1596 bp ORF. The transcript has been detected in all tissues tested to date.
Protein
Description 531-amino acid protein (64 kD); termed parafibromin.
Expression
Ubiquitously expressed.
Localisation
Nuclear, bipartite nuclear localization signal.
Function
CDC73 is a tumor suppressor gene encoding a protein called parafibromin. Parafibromin is a member of the human RNA polymerase II-associated complex, Paf1.
The human Paf1 complex is composed of parafibromin, LEO1, PAF1, and CTR9. Parafibromin's interaction with this complex is dependent on its C-terminal domain, which is deleted in ca. 80% of clinically relevant mutations.
Homology
Parafibromin shares 54% identity and 67% similarity with the D. melanogaster ortholog and 25% identity and 45% similarity with the C. elegans ortholog. There were no homologies to known protein domains, but moderate identity (32%) and similarity (54%) to the S. cerevisiae ortholog, Cdc73.
Mutations

Germinal
Various types of mutations often leading to inactivation of protein.
Somatic
Various somatic inactivating mutations found in sporadic parathyroid carcinoma.
Implicated in
Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT) Disease HPT-JT is an autosomal dominant, multiple neoplasia syndrome. Oncogenesis HPT-JT syndrome is primarily characterized by hyperparathyroidism due to parathyroid tumors.
Thirty percent of individuals with HPT-JT also develop ossifying fibromas, primarily of the mandible and maxilla, which are distinct from the brown tumors associated with severe hyperparathyroidism. Kidney lesions also occur in HPT-JT as bilateral cysts, renal hamartomas or Wilms tumors.
Familial isolated hyperthyroidism
Disease Familial isolated primary hyperparathyroidism is an autosomal dominant disorder that can represent an early stage of either the multiple endocrine neoplasia type 1 (MEN1) or hyperparathyroidism-jaw tumor (HPT-JT) syndromes; or alternatively caused by a distinct entity involving another locus. 
Sporadic parathyroid carcinoma
Sporadic renal tumors
Cytogenetics Loss of heterozygosity (LOH) of HRPT2 was found in clear cell, papillary, chromophobe renal cell carcinomas, oncocytomas, and Wilms tumors. In addition, two novel HRPT2 point mutations were detected in clear cell carcinoma and Wilms tumor.
